Clinical Trials
21 results for Prostate Cancer
Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer
- Condition: Prostate Cancer Recurrent
- Intervention: Radiation: HDR brachytherapy
- Study ID: NCT02560181
Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease
- Condition: Prostatic Neoplasms
- Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
- Study ID: NCT01913106
68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans
- Condition: Prostate Adenocarcinoma
- Intervention: Radiation: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Procedure: Magnetic Resonance Imaging, Procedure: Positron Emission Tomography
- Study ID: NCT02624518
Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time
- Condition: Prostate Cancer, Prostate Cancer Recurrent
- Intervention: Drug: Metformin Hydrochloride Extended Release 750mg
- Study ID: NCT02176161
MRI-Guided HDR Brachytherapy for Prostate Cancer
- Condition: Patients With Prostate Cancer
- Intervention: Procedure: MRI Guided Needles to deliver HDR Brachytherapy, Procedure: MRI Guided Needles to deliver HDR Brachytherapy
- Study ID: NCT00913939
Safety and Efficacy of Salvage Lymph Node Dissection in Prostate Cancer Patients With Nodal Recurrence After Radical Prostatectomy With Curative Intent - a Prospective Single Center Phase I/II Study
- Condition: Prostate Cancer Recurrent
- Intervention: Procedure: Salvage lymph node dissection
- Study ID: NCT02974075
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
- Condition: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Intervention: Drug: Abiraterone Acetate, Drug: Niclosamide, Drug: Prednisone
- Study ID: NCT02807805
A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer
- Condition: Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
- Intervention: Drug: Goserelin, Drug: Estradiol
- Study ID: NCT00303784
A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
- Condition: Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer
- Intervention: Drug: Durvalumab, Drug: Tremelimumab, Drug: Poly ICLC
- Study ID: NCT02643303
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
- Condition: Prostate
- Intervention: Drug: Olaparib
- Study ID: NCT03047135
Fluorine-18 - 2-(3-(1-carboxy-5-[(6-[18F]Fluoro-pyridine-3-carbonyl)-Amino]-Pentyl)-Ureido)-Pentanedioic Acid (18F-DCFPyL) Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of Recurrent Prostate Cancer
- Condition: Prostatic Neoplasms, Prostate Cancer
- Intervention: Drug: PSMA PET/CT scan
- Study ID: NCT02899312
(18)F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
- Condition: Prostate Neoplasms, Neoplasms, Prostatic, Prostate Cancer, Cancer Of Prostate
- Intervention: Drug: 18F-DCFPyL
- Study ID: NCT03181867
PSMA PET Imaging of Recurrent Prostate Cancer
- Condition: Prostate Adenocarcinoma, Prostate Cancer
- Intervention: Drug: Ga-HBED-iPSMA PET, Diagnostic Test: CT, Diagnostic Test: MRI
- Study ID: NCT03204123
A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
- Condition: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Intervention: Drug: Enzalutamide, Drug: Niclosamide
- Study ID: NCT03123978
Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate
- Condition: Locally Recurrent Prostate Cancer
- Intervention: Radiation: Stereotactic Body Radiotherapy
- Study ID: NCT03073278
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Apalutamide, Drug: Degarelix, Drug: Abiraterone Acetate, Drug: Prednisone
- Study ID: NCT03009981
A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer
- Condition: Non-Resectable Pancreatic Cancer
- Intervention: Biological: BPX-601, Drug: Rimiducid
- Study ID: NCT02744287
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies
- Condition: Prostate Cancer
- Intervention: Drug: Testosterone cypionate, Drug: Testosterone Enanthate, Drug: Abiraterone acetate, Drug: Enzalutamide
- Study ID: NCT02090114
Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
- Condition: Recurrent Prostate Cancer
- Intervention: Drug: Verteporfin, Device: SpectraCure P18 System
- Study ID: NCT03067051
A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer
- Condition: Biochemically Recurrent Prostate Carcinoma
- Intervention: Drug: Gallium Ga 68-labeled PSMA-11, Procedure: Positron Emission Tomography
- Study ID: NCT04216134
PSMA-PET Registry for Recurrent Prostate Cancer Following Radical Prostatectomy
- Condition: Recurrent Prostate Cancer
- Intervention: Diagnostic Test: [18F]-DCFPyL PET/ CT scan (PSMA PET)
- Study ID: NCT03718260